Key Takeaways
- • Galux's AI-driven de novo antibody design platform (GaluxDesignV3) successfully engineered antibodies for six therapeutic targets with atomic-accuracy structural precision, including one target lacking an experimentally resolved protein structure—establishing a new benchmark for computational antibody discovery.
- • The company raised $29 million (₩42 billion) in Series B funding led by Yuanta Investment in February 2026, positioning the Seoul-based biotech to commercialize AI-powered rational design methods across drug development pipelines.
- • Galux-designed antibodies demonstrated affinity, activity, and developability metrics comparable to commercial reference antibodies, with engineered binders capable of distinguishing closely related protein subtypes and mutants—validating precision molecular design for therapeutic applications.
- • The platform outperforms traditional phage display methodologies within constrained design budgets and demonstrates the viability of computational antibody design as a primary discovery modality rather than a complementary screening tool.
- • Strategic collaboration with HanAll Biopharma signals expansion into oncology drug discovery, leveraging Galux's AI design capabilities with global development expertise to accelerate therapeutic candidate advancement.
Summary
Galux Inc., a Seoul-based biotech firm, has demonstrated significant competitive advantages in AI-driven antibody design, advancing computational methods to rival and exceed traditional discovery approaches. The company's latest GaluxDesignV3 platform achieved de novo antibody engineering across six distinct therapeutic targets, including a landmark case in which no experimentally resolved target protein structure was available—a critical validation milestone that underscores the precision of structure prediction underlying the design method. According to the company's peer-reviewed research deposited on bioRxiv, designed antibodies exhibited binding specificity and sensitivity metrics comparable to established commercial antibodies, with engineered variants capable of discriminating between closely related protein subtypes and mutant variants.
The technical achievement reflects atomic-accuracy structure prediction enabling rational, rather than empirical, antibody discovery. Galux's approach combines computational design of light and heavy chain variable domains (102 designed light chain sequences with 10,000 designed heavy chain sequences per target) with yeast display screening to identify optimized binders. This methodology outperforms phage display panning within limited design budgets and establishes computational antibody design as a viable primary discovery modality for therapeutic molecule development. The consistency between AI-designed antibody structures and cryo-electron microscopy experimental structures validates the platform's precision in predicting functional binding geometry.
Financially, Galux closed a $29 million Series B funding round in February 2026, led by Yuanta Investment, bringing total capital deployed toward commercializing the platform. The funding supports expansion of the company's go-to-market strategy, including a strategic collaboration announced with HanAll Biopharma to co-develop oncology therapeutics leveraging Galux's design engine alongside HanAll's global development and regulatory expertise. This partnership positioning reflects institutional investor confidence in the platform's differentiation within a competitive AI-driven drug discovery landscape.
The competitive environment has intensified, with MIT demonstrating that machine learning-based CDR (complementarity-determining region) design can outperform traditional phage display approaches under resource constraints. Galux's demonstrated ability to engineer antibodies for targets lacking structural data and to achieve commercial-grade developability metrics positions the company as a category leader in moving AI-driven antibody design from research validation to clinical-stage therapeutics manufacturing, a transition that will determine long-term valuation and strategic exit potential.
The technical achievement reflects atomic-accuracy structure prediction enabling rational, rather than empirical, antibody discovery. Galux's approach combines computational design of light and heavy chain variable domains (102 designed light chain sequences with 10,000 designed heavy chain sequences per target) with yeast display screening to identify optimized binders. This methodology outperforms phage display panning within limited design budgets and establishes computational antibody design as a viable primary discovery modality for therapeutic molecule development. The consistency between AI-designed antibody structures and cryo-electron microscopy experimental structures validates the platform's precision in predicting functional binding geometry.
Financially, Galux closed a $29 million Series B funding round in February 2026, led by Yuanta Investment, bringing total capital deployed toward commercializing the platform. The funding supports expansion of the company's go-to-market strategy, including a strategic collaboration announced with HanAll Biopharma to co-develop oncology therapeutics leveraging Galux's design engine alongside HanAll's global development and regulatory expertise. This partnership positioning reflects institutional investor confidence in the platform's differentiation within a competitive AI-driven drug discovery landscape.
The competitive environment has intensified, with MIT demonstrating that machine learning-based CDR (complementarity-determining region) design can outperform traditional phage display approaches under resource constraints. Galux's demonstrated ability to engineer antibodies for targets lacking structural data and to achieve commercial-grade developability metrics positions the company as a category leader in moving AI-driven antibody design from research validation to clinical-stage therapeutics manufacturing, a transition that will determine long-term valuation and strategic exit potential.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.